BioSpace News Archive

Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.

BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.

Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.

The U.S. Food and Drug Administration (FDA) approved Indivior’s Perseris for schizophrenia.

Berwyn, Pennsylvania attorneys RM Law, P.C. filed a class action lawsuit against Acadia Pharmaceuticals. The suit was filed on behalf of “all persons or entities” that bought company stock between July 17, 2014 and July 3, 2018.

It’s pretty easy to complain about the price of drugs. Drug companies typically spend billions of dollars to develop a drug, and often spend billions of dollars to develop drugs that never get approved. But a surprising critic of the U.S. system of pricing drugs is Leonard Schleifer.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Phoenix, Arizona-based Insys Therapeutics for its buprenorphine sublingual spray for moderate-to-severe acute pain.

Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.

RedHill Biopharma, with offices in Tel Aviv, Israel and Raleigh, North Carolina, announced positive topline data from its first Phase III trial of RHB-104 for Crohn’s disease. It met all primary endpoint and key secondary endpoints.

Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogues may be effective treatments for Parkinson’s disease.